|
|
Article: NicOx S.A. and Merck & Co., Inc. Sign Major Exclusive Worldwide Agreement in Antihypertensive Field.
- Article from:
- Business Wire
- Article date:
- March 21, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SOPHIA ANTIPOLIS, France & WHITEHOUSE STATION, N.J. -- NicOx S.A. and Merck & Co., Inc., today announced that they have signed a major new agreement to collaborate on the development of new antihypertensive drugs using NicOx's proprietary nitric oxide-donating technology. This agreement follows the successful completion of the companies' research collaboration, which has generated promising results.
Under the terms of the agreement, NicOx will receive an upfront payment of EUR 9.2 million (approximately US $11.2 million) and is eligible for potential further milestone payments of EUR 279 million (approximately US $340.2 million). NicOx has the option to ...